Physiotherapy Treatment Plan in Allergic Bronchopulmonary Aspergillosis: Case Report

Obstructive Pulmonary Disease Clinical Trial

Official title:

Effects of a Respiratory Physiotherapy Treatment Plan in Allergic Bronchopulmonary Aspergillosis: Case Report

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04748900
• Other study ID #: 04/02/2021
• Status: Completed
• Start date: October 1, 2020
• Est. completion date: February 5, 2021

Study information

• Verified date: February 2021
• Source: Universidad Católica de Ávila
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

A spirometry study is performed in a patient diagnosed with allergic bronchopulmonary aspergillosis. An initial measurement is carried out and the patient is then put on a four-week physiotherapy treatment plan. Four spirometry measurements were taken to assess different variables and an improvement in all the spirometry values was established.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: February 5, 2021
• Est. primary completion date: February 3, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

• woman
• diagnosis of respiratory insufficiency due to allergic bronchopulmonary aspergillosis
• over 50 years of age
• under 80 years of age

Exclusion Criteria:

• male
• not have a diagnosis of respiratory insufficiency due to allergic bronchopulmonary aspergillosis
• under 50 years of age
• over 80 years of age

Related Conditions & MeSH terms

• Aspergillosis
• Lung Diseases
• Lung Diseases, Obstructive
• Obstructive Pulmonary Disease
• Pulmonary Aspergillosis

Intervention

Diagnostic Test:
• spirometer
different values are measured on the spirometer after training in respiratory physiotherapy.

Locations

Country	Name	City	State
Spain	Universidad Católica de Ávila	Ávila

Sponsors (1)

Lead Sponsor	Collaborator
Universidad Católica de Ávila

Country where clinical trial is conducted

Spain, 

References & Publications (9)

Bonaiti G, Merati V, Pesci A, Faverio P. Allergic bronchopulmonary aspergillosis screening in bronchiectasis: is there always a precise answer to a clear question? Eur Ann Allergy Clin Immunol. 2019 Jan;51(1):41-43. doi: 10.23822/EurAnnACI.1764-1489.62. — View Citation

Cui L, Liu H, Sun L. Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease. Pak J Med Sci. 2019 Mar-Apr;35(2):500- — View Citation

Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013 May;51(4):361-70. doi: 10.3109/13693786.2012.738312. Epub 2012 Dec 4. — View Citation

HINSON KF, MOON AJ, PLUMMER NS. Broncho-pulmonary aspergillosis; a review and a report of eight new cases. Thorax. 1952 Dec;7(4):317-33. — View Citation

Kalaiyarasan, Jain AK, Puri M, Tayal D, Singhal R, Sarin R. Prevalence of allergic bronchopulmonary aspergillosis in asthmatic patients: A prospective institutional study. Indian J Tuberc. 2018 Oct;65(4):285-289. doi: 10.1016/j.ijtb.2018.04.007. Epub 2018 — View Citation

Lareau SC, Fahy B. Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2018 Nov 15;198(10):P19-P20. doi: 10.1164/rccm.19810P19. — View Citation

Oguma T, Taniguchi M, Shimoda T, Kamei K, Matsuse H, Hebisawa A, Takayanagi N, Konno S, Fukunaga K, Harada K, Tanaka J, Tomomatsu K, Asano K. Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey. Allergol Int. 2018 Jan;67(1):79-84. doi: 1 — View Citation

Patel G, Greenberger PA. Allergic bronchopulmonary aspergillosis. Allergy Asthma Proc. 2019 Nov 1;40(6):421-424. doi: 10.2500/aap.2019.40.4262. Review. — View Citation

Sehgal IS, Choudhary H, Dhooria S, Aggarwal AN, Bansal S, Garg M, Behera D, Chakrabarti A, Agarwal R. Prevalence of sensitization to Aspergillus flavus in patients with allergic bronchopulmonary aspergillosis. Med Mycol. 2019 Apr 1;57(3):270-276. doi: 10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total volume	ml	3 months
Primary	Vital capacity	ml	3 months
Primary	Expiratory reserve volume	ml	3 months
Primary	Inspiratory reserve volume	ml	3 months
Primary	Inspiratory capacity	ml	3 months
Primary	Inspiration time	seconds	3 months
Primary	Expiratory time	seconds	3 months
Secondary	Total time	seconds	3 months
Secondary	Percentage inspiratory time	seconds	3 months